"Omics"-informed drug and biomarker discovery: Opportunities, challenges and future perspectives

Proteomes

Volumn 4, Issue 3, 2016, Pages

  Matthews, Holly ^a   Hanison, James ^b   Nirmalan, Niroshini ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF SALFORD   (United Kingdom)

Author keywords

Drug discovery; Genomics; Metabolomics; Omics; Proteomics

Indexed keywords

EID: 85017093581     PISSN: None     EISSN: 22277382     Source Type: Journal    
DOI: 10.3390/proteomes4030028     Document Type: Review

References (64)

1. Kaitin, K.I.; DiMasi, J.A. Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000-2009. Clin. Pharmacol. Ther. 2011, 89, 183-188
2. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 2009, 8, 959-968
3. Breyer, M.D. Improving productivity of modern day drug discovery. Exp. Opin. Drug Discov. 2014, 9, 115-118
4. Thompson, S.; Craven, R.A.; Nirmalan, N.J.; Harnden, P.; Selby, S.J.; Banks, R.E. Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue. Proteom. Clin. Appl. 2012
5. Brown, A.; Casadevall, A. Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables in biomedical research. Proc. Natl. Acad. Sci. USA 2015, 112, 11335-11340
6. Ioannidis, J. Why most published research findings are false. PLoS Med. 2005, 2, 124
7. Prinz, F.; Schlange, T.; Asadullah, K. Believe it or not: How much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 2011, 10, 328-329
8. Matthews, H.; Usman-Idris, M.; Khan, F.; Read, M.; Nirmalan, N.J. Drug repositioning as a route to anti-malarial drug discovery: Preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malar. J. 2013, 12, 359-370
9. Publication Guidelines for the Analysis and Documentation of Peptide and Protein Identifications. Available online: http://www.mcponline.org/site/misc/ParisReport_Final.xhtml (accessed on 8 August 2016)
10. Drug Discovery and Development, Understanding the R&D Process. Available online: http://cmidd. northwestern.edu/files/2015/10/Drug_RD_Brochure-12e7vs6.pdf (accessed on 8 August 2016)
11. Biopharmaceutical Research and Development, the Process Behind New Medicines. Available online: http://www.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf (accessed on 8 August 2016)
12. Norris, S.M.P.; Pankevich, D.; Davis, M.; Altevogt, B.M. Improving and Accelerating Therapeutic Development for Neurosystem Disorders; National Academic Press: Washington, DC, USA, 2014
13. Bunnage, M.E. Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 2011, 7, 335-339
14. Seok, J.; Warren, H.S.; Cuenca, A.G.; Mindrinos, M.N.; Baker, H.V.; Xu, W.; Richards, D.R.; McDonald-Smith, G.P.; Gao, H.; Hennessy, L.; et al. Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA 2013, 110, 3507-3512
15. Young, J.E.; Goldstein, L.S. Alzheimer's disease in a dish: Promises and challenges of human stem cell models. Hum. Mol. Genet. 2012, 21, 82-89
16. Orloff, J.; Douglas, F.; Pinheiro, J.; Levinson, S.; Branson, M.; Chaturvedi, P.; Ette, E.; Gallo, P.; Hirsch, G.; Mehta, C.; et al. The future of drug development: Advancing clinical trial design. Nat. Rev. Drug Discov. 2009, 8, 949-957
17. Elebring, T.; Gill, A.; Plowright, A.T. What is the most important approach in current drug discovery: Doing the right things or doing things right? Drug Discov. Today. 2012, 17, 1166-1169
18. Debouck, C.; Metcalf, B. The impact of genomics on drug discovery. Ann. Rev. Pharmacol. Toxicol. 2000, 40, 193-207
19. Oliver, S.G. From gene to screen with yeast. Curr. Opin. Genet. Dev. 1997, 7, 405-409
20. Helali, A.M.; Iti, F.M.; Mohamed, I.N. Cathepsin K inhibitors: A novel target but promising approach in the treatment of osteoporosis. Curr. Drug Targets 2013, 14, 1591-1600
21. Lappano, R.; Maggiolini, M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 2011, 10, 47-60
22. Land, M.; Hauser, L.; Jun, S.; Nookaew, I.; Leuze, M.R.; Ahn, T.; Karpinets, T.; Lund, O.; Kora, G.; Wassenaar, T.; et al. Insights from 20 years of bacterial genome sequencing. Funct. Integr. Genom. 2015, 15, 141-161
23. Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H.W.H.; Neefs, J.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307, 223-227
24. Wasinger, V.C.; Cordwell, S.J.; Cerpa-Poljak, A.; Yan, J.X.; Gooley, A.A.; Wilkins, M.R.; Duncan, M.W.; Harris, R.; Williams, K.L.; Humphery-Smith, I. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 1995, 16, 1090-1094
25. Wilkins, M. Proteomics data mining. Exp. Rev. Prot. 2009, 6, 599-603
26. He, Q.; Chiu, J. Proteomics in Biomarker discovery and drug development. J. Cell. Biochem. 2003, 89, 868-886
27. Bichsel, V.E.; Liotta, L.A.; Petricoin, E.F. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J. 2001, 7, 69-78
28. Wang, K.; Huang, C.; Nice, H. Recent advances in proteomics: Towards the human proteome. Biomed. Chromatogr. 2014, 28, 848-857
29. Garbis, S.; Lubec, G.; Fountoulakis, M. Limitations of current proteomics technologies. J. Chromatogr. A 2005, 1077, 1-18
30. Moxona, J.V.; Padulab, M.P.; Herbert, B.R.; Golledgea, J. Challenges, current status and future perspectives of proteomics in improving understanding, diagnosis and treatment of vascular disease. Eur. J. Vasc. Endovasc. Surg. 2009, 38, 346-355
31. Hood, L.E.; Omenn, G.S.; Moritz, R.L.; Aebersold, R.; Yamamoto, K.R.; Amos, M.; Hunter-Cevera, J.; Locascio, L. New and improved proteomics technologies for understanding complex biological systems: Addressing a grand challenge in the life sciences. Proteomics 2012, 12, 2773-2783
32. Poste, G. Biospecimens, biomarkers, and burgeoning data: The imperative for more rigorous research standards. Trends Mol. Med. 2012, 18, 717-722
33. Goldstein, R.L.; Yang, S.N.; Taldone, T.; Chang, B.; Gerecitano, J.; Elenitoba-Johnson, K.; Shaknovich, R.; Tam, W.; Leonard, J.P.; Chiosis, G.; et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J. Clin. Investig. 2015, 125, 4559-4571
34. Reddy, P.J.; Jain, R.; Paik, Y.; Downey, R.; Ptolemy, A.S.; Ozdemir, V.; Srivastava1, S. Personalized Medicine in the Age of Pharmacoproteomics: A close up on India and need for social science engagement for responsible innovation in post-proteomic biology. Curr. Pharmacogenom. Pers. Med. 2011, 9, 67-75
35. Rabilloud, T.; Lelong, C. Two-dimensional gel electrophoresis in proteomics: A tutorial. J. Proteom. 2011, 74, 1829-1841
36. Bunai, K.; Yamane, K. Effectiveness and limitation of two-dimensional gel electrophoresis in bacterial membrane protein proteomics and perspectives. J. Chromatogr. B 2005, 815, 227-236
37. Lilley, K.; Beynon, R.J.; Eyers, C.E.; Hubbard, S.J. Focus on Quantitative Proteomics. Proteomics 2015, 15, 3101-3103
38. Nirmalan, N.; Hughes, C.; Peng, J.; Mckenna, T.; Langridge, J.; Cairns, D.; Harnden, P.; Selby, P.; Banks, R. Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed paraffin embedded tissue proteome for biomarker investigations. J. Proteom. Res. 2011, 4, 896-906
39. Trinh, H.V.; Grossmann, J.; Gehrig, P.; Roschitzki, B.; Schlapbach, R.; Greber, U.F.; Hemmi, S. iTRAQ-based and label-free proteomics approaches for studies of human adenovirus infections. Int. J. Proteom. 2013, 2013, 581862
40. Fiehn, O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp. Funct. Genom. 2001, 2, 155-168
41. Fillet, M.; Frédérich, M. The emergence of metabolomics as a key discipline in the drug discovery process. Drug Discov. Today Technol. 2015, 13, 19-24
42. Reily, M.; Tymiak, A. Metobolomics in the pharmaceutical industry. Drug Discov. Today Technol. 2015, 13, 25-31
43. Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 2016, 15, 473-484
44. Cuperlovic-Culf, M.; Culf, A.S.; Morin, P.; Touaibi, M. Application of Metabolomics in Drug Discovery, Development and Theranostics. Curr. Metabolomics 2013, 1, 41-57
45. Monteiro, M.S.; Carvalho, M.; Bastos, M.L.; Guedes de Pinho, P. Metabolomics analysis for biomarker discovery: Advances and challenges. Curr. Med. Chem. 2013, 20, 257-271
46. Ramirez, T.; Daneshian, M.; Kamp, H.; Kamp, H.; Bois, F.Y.; Clench, M.R.; Coen, M.; Donley, B.; Fischer, S.M.; Ekman, D.R.; et al. Metabolomics in toxicology and preclinical research. ALTEX 2013, 30, 209-225
47. Desiere, D.; Deutsch, E.W.; King, N.L.; Nesvizhskii, A.; Mallick, P.; Eng, J.; Chen, S.; Eddes, J.; Loevenich, S.L.; Aebersold, R. The PeptideAtlas project. Nucleic Acid Res. 2005, 34 (Suppl. 1), D655-D658
48. Berglund, L.; Björling, E.; Oksvold, P.; Fagerberg, L.; Asplund, A.; Szigyarto, C.A.; Persson, A.; Ottosson, J.; Wernérus, H.; Nilsson, P.; et al. Genecentric human protein atlas for expression profiles based on antibodies. Mol. Cell. Proteom. 2008, 7, 2019-2027
49. Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, J.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; et al. Towards a knowledge based Human Protein Atlas. Nat. Biotechnol. 2010, 28, 1248-1250
50. Gaudet, P.; Michel, P.; Zahn-Zabal, M.; Cusin, I.; Duek, P.D.; Evalet, O.; Gateau, A.; Gleizes, A.; Pereira, M.; Teixeira, D.; et al. The neXtProt knowledge base on human proteins: Current status. Nucl. Acids Res. 2015, 43, 764-770
51. Khanna, I. Drug discovery in pharmaceutical industry: Productivity challenges and trends. Drug Discov. Today 2012, 17, 1088-1102
52. Arrowsmith, J. Trial watch: Phase II failures. Nat. Rev. Drug. Discov. 2011, 10, 328-329
53. Graul, A.I.; Cruces, E.; Stringer, M. The year's new drugs & biologics. Drugs Today (Barc.) 2015, 51, 37-87
54. Shim, J.S.; Liu, J.O. Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs. Int. J. Biol. Sci. 2014, 10, 654-663
55. Corbett, A.; Pickett, J.; Burns, A.; Corcoran, J.; Dunnett, S.B.; Edison, P.; Hagan, J.J.; Holmes, C.C.; Jones, E.; Katona, C.; et al. Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov. 2012, 11, 833-846
56. Lucumi, E.; Darling, C.; Jo, H.; Napper, A.D.; Chandramohandas, R.; Fisher, N.; Shone, A.E.; Jing, H.; Ward, S.A.; Biagini, G.A.; et al. Discovery of potent small molecule inhibitors of multi drug-resistant Plasmodium falciparum using a novel miniaturised high throughput luciferase-based assay. Antimicrob. Agents Chemother. 2010, 54, 3579-3604
57. Temesi, G.; Bolgár, B.; Arany, A.; Szalai, C.; Antal, P.; Mátyus, P. Early repositioning through compound set enrichment analysis: A knowledge-recycling strategy. Future Med. Chem. 2014, 6, 563-575
58. Silber, B.M. Omics in drug discovery: From small molecule leads to clinical candidates. In The Omics Applications in Neuroscience, 2nd ed.; Oxford University Press: Oxford, UK, 2014; Chapter 16
59. Silber, B.M. Driving drug Discovery: The fundamental role of academic labs. Drug Discov. 2010, 2, 16-20
60. Goodman, M. Market watch: Pharma industry performance metrics: 2007-2012E. Nat. Rev. Drug Discov. 2009, 7, 795
61. Paul, S.M.; Mytelka, D.S.; Dunwiddie, C.T.; Persinger, C.C.; Munos, B.H.; Lindborg, S.R.; Schacht, A.L. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9, 203-214
62. Cuatrecasas, P. Drug discovery in jeopardy. J. Clin. Investig. 2006, 116, 2837-2842
63. Subramaniam, S.; Dugar, S. Outsourcing drug discovery to India and China: From surviving to thriving. Drug Discov. Today 2012, 17, 1055-1058
64. Garnier, J. Rebuilding the R&D engine in big pharma. Harv. Bus. Rev. 2008, 86, 68-76